Osmolex ER is a Small Molecule owned by Supernus Pharmaceuticals, and is involved in 1 clinical trial, which was completed.

Amantadine hydrochloride extended release elicits central nervous system activity. The drug candidate exhibits anticholinergic effect through inhibition of N-methyl-D-aspartic acid (NMDA) receptor-mediated stimulation of acetylcholine. The drug candidate may cause greater amounts of dopamine to be released in the brain.

The revenue for Osmolex ER is expected to reach a total of $50m through 2033. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Osmolex ER NPV Report.

Osmolex ER is currently owned by Supernus Pharmaceuticals.

Osmolex ER Overview

Amantadine hydrochloride (Osmlex ER) is developed based on osmodex technology acts as anti parkinson's agent. It is formulated as extended release coated tablets for oral route of administration. Osmlex ER is indicated for the treatment of Parkinson's disease and for the treatment of drug-induced extrapyramidal reactions in adult patients.

Supernus Pharmaceuticals Overview

Supernus Pharmaceuticals is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company’s neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; Trokendi XR (topiramate), an initial monotherapy in patients with partial-onset of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome; Apokyn, and Xadago for Parkinson’s disease and Myobloc for cervical dystonia and sialorrhea in adults. Its major pipeline products include SPN-830, SPN-812, SPN-817, and SPN-820. The company’s technology platforms include Microtrol (multi particulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). Supernus Pharmaceuticals is headquartered in Rockville, Maryland, the US.

The company reported revenues of (US Dollars) US$579.8 million for the fiscal year ended December 2021 (FY2021), an increase of 11.4% over FY2020. In FY2021, the company’s operating margin was 14.8%, compared to an operating margin of 33.4% in FY2020. In FY2021, the company recorded a net margin of 9.2%, compared to a net margin of 24.4% in FY2020. The company reported revenues of US$170.1 million for the second quarter ended June 2022, an increase of 11.5% over the previous quarter.

Quick View – Osmolex ER

Report Segments
  • Innovator (Non-NME)
Drug Name
  • Osmolex ER
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.